The truncated brain-derived neurotrophic factor (BDNF) receptors (truncated TrkB and sarc homology containing TrkB [TrkB-Shc]) are alternative transcripts of the full-length TrkB receptor (TrkB-TK1) that produce isoforms capable of binding to BDNF but not being able to mediate the classic neurotrophic response via tyrosine kinase signaling. We hypothesized that in the dorsolateral prefrontal cortex (DLPFC) of people with schizophrenia, truncated TrkB receptors (TK2 and Shc) would be altered and may contribute to deficits in BDNF function. Using a large cohort of controls and schizophrenics (n 5 72/72), we measured mRNA expression of the full-length TrkB receptor, TrkB-TK1 and the truncated TrkB receptors, TrkB-TK2 and TrkB-Shc, by quantitative real-time polymerase chain reaction and protein expression by western blotting. We found highly significant increases in mRNA expression of both truncated TrkB receptor isoforms in people with schizophrenia. When we examined the full-length TrkB-TK1:truncated TrkB ratios, we observed significant decreases in schizophrenia both on the mRNA and protein level. We found a slight reduction in TrkB-TK1 mRNA and a significant reduction in TrkB-TK1 protein expression in schizophrenia, which was evident in females. No gender-specific changes were found for the truncated TrkB receptors. Diagnostic changes in TrkB-TK1 mRNA and protein may be subtle and/or gender-specific, whereas changes in TrkB-TK2 and TrkB-Shc expression are robust and may generalize to both males and females with schizophrenia. Increased truncated TrkB receptors may contribute to reduced overall BDNF/tyrosine receptor kinase B (TrkB) signaling and lead to reduced neuronal plasticity in the DLPFC in schizophrenia suggesting that therapies aimed at ameliorating neurotrophin deficits may need to consider blocking excessive truncated TrkB function.
The truncated brain-derived neurotrophic factor (BDNF) receptors (truncated TrkB [TrkB-TK2] and sarc homology containing TrkB [TrkB-Shc]) are alternative transcripts of the full-length TrkB receptor (TrkB-TK1) that produce isoforms capable of binding to BDNF but not being able to mediate the classic neurotrophic response via tyrosine kinase signaling. We hypothesized that in the dorsolateral prefrontal cortex (DLPFC) of people with schizophrenia, truncated TrkB receptors (TK2 and Shc) would be altered and may contribute to deficits in BDNF function. Using a large cohort of controls and schizophrenics (n 5 72/72), we measured mRNA expression of the full-length TrkB receptor, TrkB-TK1 and the truncated TrkB receptors, TrkB-TK2 and TrkB-Shc, by quantitative real-time polymerase chain reaction and protein expression by western blotting. We found highly significant increases in mRNA expression of both truncated TrkB receptor isoforms in people with schizophrenia. When we examined the full-length TrkB-TK1:truncated TrkB ratios, we observed significant decreases in schizophrenia both on the mRNA and protein level. We found a slight reduction in TrkB-TK1 mRNA and a significant reduction in TrkB-TK1 protein expression in schizophrenia, which was evident in females. No gender-specific changes were found for the truncated TrkB receptors. Diagnostic changes in TrkB-TK1 mRNA and protein may be subtle and/or gender-specific, whereas changes in TrkB-TK2 and TrkB-Shc expression are robust and may generalize to both males and females with schizophrenia. Increased truncated TrkB receptors may contribute to reduced overall BDNF/tyrosine receptor kinase B (TrkB) signaling and lead to reduced neuronal plasticity in the DLPFC in schizophrenia suggest
Introduction
In schizophrenia, people show cognitive deficits linked to abnormalities in the function of the dorsolateral prefrontal cortex (DLPFC). 1 While multiple lines of evidence support the idea of altered neuronal function in schizophrenia, a definitive mechanism for this neuronal deficit is elusive. The neurotrophin, brain-derived neurotrophic factor (BDNF), is consistently decreased in the DLPFC of people with schizophrenia (in at least 4 postmortem brain cohorts). [2] [3] [4] Neurotrophins are potent regulators of neuronal maturation, differentiation, survival, plasticity, and function [5] [6] [7] [8] ; and their effects are mediated through high-affinity tropomyosin receptor kinase receptors (Trks). 9, 10 People with schizophrenia not only show reduced expression of BDNF but they also demonstrate reductions in full-length TrkB receptors (TrkB-TKþ). 3, 11 Moreover, reductions in TrkB-TKþ were speculated to be more deleterious to interneuron health and viability than BDNF reductions alone. 3 However, the function of tyrosine receptor kinase B (TrkB) receptors depends not only on the abundance of TrkB-TKþ but also on the levels of other TrkB splice variants known to be expressed in the human DLPFC. 12 The full-length (TrkB-TKþ) and truncated TrkB receptors (TrkB-TK� and sarc homology containing TrkB [TrkB-Shc] ) are generated by alternative splicing and are the 3 best characterized and most abundant TrkB isoforms in the brain 13 ( figure 1 ). The high-affinity TrkB-TKþ contains a catalytic tyrosine kinase domain, is expressed almost exclusively in neurons within the human prefrontal Truncated TrkB in Schizophrenia cortex, 11 and is necessary for activating second messenger signaling and mediating the neurotrophic effects of BDNF. 9, 14 TrkB-TK� lacks the catalytic tyrosine kinase domain but contains a short isoform-specific cytoplasmic domain. 15 It is expressed in both neurons (pyramidal and interneurons) and glia (astrocytes) [16] [17] [18] and in glia, TrkB-TK� may inhibit neuronal neurotrophin signaling by sequestering or trapping neurotrophins to prevent binding. 19, 20 Alternatively, TrkB-TK� has been shown in vitro cell culture to act as a dominant-negative receptor by forming inactive heterodimers with TrkB-TKþ to prevent neurotrophin signaling. 21, 22 Considering that neurons can co-express both TrkB-TKþ and TrkB-TK�, 23 this event may occur in vivo. Thus, the cellular response to BDNF has been proposed to depend on the relative levels of the TrkB-TKþ and TrkB-TK� isoforms. 21, 24 The other truncated TrkB receptor isoform, TrkB-Shc, contains a sarc homolgy binding site (Shc) in the juxtamembrane domain similar to TrkB-TKþ; however, it contains a unique truncated carboxy-terminus which also lacks the tyrosine kinase domain and can act as a negative regulator of TrkB-TKþ. 13 Previously, we found that levels of TrkB-TK� mRNA are robust and at least equivalent to TrkB-TKþ mRNA levels in the human cortex by Northern Blotting 25 suggesting that TrkB-TK� may contribute significantly to cortical neurotrophin response. Thus, efforts to stimulate BDNF or TrkB-TKþ signaling in schizophrenia may be limited without knowing if alterations in truncated TrkB receptor isoforms also exist in the diseased state. Although the truncated TrkB isoforms are critical in determining the cellular response to BDNF, no study has been published that specifically examines the mRNA and/or protein expression of the truncated TrkB receptors, (TrkB-TK�/TrkB-Shc) in schizophrenia. In this current study, we determined whether mRNA and/or protein expression of the TrkB receptors, TrkB-TKþ, TrkB-TK�, and TrkB-Shc or their ratios of expression, are altered in the DLPFC of people with schizophrenia. We hypothesized that in addition to decreased TrkB-TKþ, people with schizophrenia may also have alterations in truncated TrkB receptor expression, either of which may interfere with normal neurotrophin signaling.
Methods

Brain Cohort
The combined cohort used in this study comprises the Tissue Resource Centre (TRC) cohort (Sydney, Australia) (n = 37 controls, n = 37 schizophrenics) and the Stanley Medical Research Institute's (SMRI) brain ''array'' collection (MD) (n = 35 controls, n = 35 schizophrenics). Cases with schizophrenia were matched to healthy controls for both cohorts. For pair matching (TRC), the following guidelines were used: (1) age at death (within 10 y), (2) brain pH (within 0.59 pH units), and (3) postmortem interval (PMI) (within 22 h). Demographic data for the combined cohort are listed in table 1. The overall quality of the RNA was high (average RNA integrity number [RIN] >7). The diagnostic groups did not differ according to age, brain pH, PMI, RIN, or brain weight (all P > .06). Anatomical dissections for the DLPFC and detailed demographics for each cohort have been published. [26] [27] [28] For the 2 different brain cohorts, the manner in which the schizophrenia cases were diagnosed (all meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria for schizophrenia) and the protocols used for tissue collection, characterization, and RNA extraction were similar.
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RNA Extraction and cDNA Synthesis
Total RNA was extracted from ;300 mg of frozen DLPFC tissue using the TRIZOL Reagent method (Life Technologies Inc, Grand Island, NY) as described. 30 RIN was assessed with high-resolution capillary electrophoresis (Agilent Technologies, Palo Alto, CA). Three aliquots of 3 lg RNA were reverse transcribed to synthesize cDNA by random hexamer priming using the SuperScript First-Strand Synthesis System (Life Technologies Inc) as described and the 3 aliquots were then pooled. 30 Quantitative Real-Time Polymerase Chain Reaction TrkB mRNA levels from cDNA were measured by Taqman (primers/probes) quantitative real-time polymerase chain reaction (qPCR) using an ABI Prism 7900HT Fast RealTime PCR System in a 384-well format as described. 31 The most optimal housekeeping genes were determined and the 3 that overlapped between the 2 cohorts were used to calculate the geometric means as previously described. 26, 32 The housekeeping genes used included b-actin (ACTB) (Cat#hs99999903-m1), ubiquitin-C (UBC) (Cat#hs00824723-m1), and TATA box-binding protein (TBP) (Cat#hs00427620-m1). The TrkB transcripts were targetedby thefollowing ABI Taqman primers/probes (Applied Biosystems): TrkB-TKþ (Cat#hs01093098-m1), TrkB-TK� (Cat#hs01093110-m1), and TrkB-Shc (custom probe Cat#AIVI3IH) (figure 1). Samples (9 ng cDNA) were run in triplicate with an 8-point standard curve using serial dilutions of pooled cDNA (from all cases) under standard cycling conditions. 31 No template and no reverse-transcription controls produced no signal. PCR data was obtained with the Sequence Detector Software (SDS version 2.0, Applied Biosystems). TrkB mRNA levels from each subject in the 2 cohorts were normalized by the geometric mean of housekeepers measured from the same subject. There was no significant difference between the housekeeping genes or geometric mean between controls and schizophrenics (all P > .15) (see online supplementary material for figure S1and Results 1 for details).
Western Blotting
Protein extraction and western blotting were conducted as described. 4, 31 Briefly, samples of equal protein (10 lg) were analyzed by 10% sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gels or 12% Bis-Tris gels (BioRad). Internal controls of pooled DLPFC homogenates were run as a correction for gel to gel variation. The primary antibody used to detect human TrkB protein was from Cell Signaling Technology (diluted 1:3000; 4°C; overnight; Cat#4603) (figure 1). b-Actin (Chemicon International, Cat#MAB1501) was probed as a protein loading control. Bands were visualized on a Chemidoc Imaging 
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System (BioRad) and quantitated by densitometry using Quantity One 1-D Analysis Software v4.6.5 (BioRad). TrkB protein levels were determined after normalizing with b-actin.
Statistical Analysis
We excluded qPCR measurement errors (TRC cohort: no more than 3/group removed; none were removed from the SMRI cohort). Population outliers (62 SDs) were excluded from both mRNA and protein analyses (in all assays for both cohorts, ;6% were outliers). Statistical analyses were conducted (StatSoft Inc, 2000, STATISTI-CA for Windows) with 2-tailed unpaired tests to assess mRNA expression of the qPCR housekeeping genes and geometric mean between controls and schizophrenics. One-tailed unpaired t tests were conducted if a directional hypothesis was employed. Pearson's Product Moment correlations were conducted to determine if any relationship existed between measured target molecules and demographic variables (see online supplementary material for Results 2). Where a relationship existed, ANCOVA was calculated. Pearson's Product Moment correlations were also conducted to assess the relationship between mRNA and protein targets. To determine the main effect of diagnosis and gender and the diagnosis 3 gender interaction effect on TrkB mRNA and protein expression and receptor ratios, 2-way ANOVA was conducted followed by Fisher Least Significant Difference (LSD) post hoc analysis. A P < .05 was considered statistically significant.
Results
mRNA Expression of TrkB Receptors
We found that TrkB-TK� and TrkB-Shc mRNAs were highly and significantly elevated (38% and 33% increase, repsectively) in the DLPFC of people with schizophrenia (ANCOVA with pH, diagnosis main effect: TrkB-TK�: F = 5.33, df = 1, 130, P = .02; ANOVA diagnosis main effect: TrkB-Shc: F = 7.61, df = 1, 132, P = .007) (figure 2B and C). ANCOVA analysis of TrkB-TKþ mRNA expression covarying for age, PMI, and RIN revealed a trend toward decreased expression in people with schizophrenia (ANCOVA: F = 3.63, df = 1, 129, P = .059) (figure 2A), but unlike the large increase in mRNAs encoding the truncated TrkB receptors, the magnitude of the decrease in TrkB-TKþ was relatively small (<10% decrease).
Protein Expression of TrkB Receptors
We found immunoreactive TrkB bands migrating at ;140 kDa and ;90 kDa in all human DLPFC samples (figure 3A) with the smaller band being more intense. The ;140 kDa band corresponding to TrkB-TKþ protein showed a significant reduction in schizophrenia (10% decrease; ANOVA diagnosis main effect: F = 10.4, df = 1, 132, P = .002) (figure 3B). The smaller TrkB immunopositive bands migrating at ;90 kDa was large and diffuse. This is likely because TrkB-TK� and TrkB-Shc are similar in size and both migrate at ;90 kDa. A trend toward increased expression was observed in the ;90 kDa TrkB protein in people with schizophrenia compared with controls (12% increase; unpaired t test: t = 1.59, df = 135, P = .057 one-tailed, figure 3C ). b-actin levels did not vary between controls and schizophrenics (P > .05). System (BioRad) and quantitated by densitometry using Quantity One 1-D Analysis Software v4.6.5 (BioRad). TrkB protein levels were determined after normalizing with b-actin.
Statistical Analysis
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mRNA Expression of TrkB Receptors
Protein Expression of TrkB Receptors
We found immunoreactive TrkB bands migrating at ;140 kDa and ;90 kDa in all human DLPFC samples (figure 3A) with the smaller band being more intense. The ;140 kDa band corresponding to TrkB-TKþ protein showed a significant reduction in schizophrenia (10% decrease; ANOVA diagnosis main effect: F = 10.4, df = 1, 132, P = .002) (figure 3B).
The smaller TrkB immunopositive bands migrating at ;90 kDa was large and diffuse. This is likely because TrkB-TK� and TrkB-Shc are similar in size and both migrate at ;90 kDa. A trend toward increased expression was observed in the ;90 kDa TrkB protein in people with schizophrenia compared with controls (12% increase; unpaired t test: t = 1.59, df = 135, P = .057 one-tailed, figure 3C ). b-actin levels did not vary between controls and schizophrenics (P > .05). The mRNA and protein levels of all 3 TrkB isoforms across individual subjects in the study were tested for correlation. We found a significant negative correlation between the 90 kDa truncated TrkB protein and TrkB-TKþ mRNA (r=�.38, P = .00001). No other significant correlations were observed between TrkB mRNA and protein.
mRNA and Protein Ratios Between Full-Length and Truncated TrkB Receptor Expression
We next determined whether the TrkB-TKþ:truncated TrkB receptor ratios were altered in schizophrenia. In the DLPFC of people with schizophrenia, we observed a highly significant reduction in the relative ratios of TrkB-TKþ:TrkB-TK� mRNA (ANOVA diagnosis main effect: F = 8.21, df = 1, 127, P = .005) (figure 4A) and TrkB-TKþ:TrkB-Shc mRNA (ANOVA diagnosis main effect: F = 5.90, df = 1, 124, P = .017) (figure 4B). Since reductions in the ratio of full-length to truncated TrkB mRNA expression were observed in schizophrenia, we tested whether the ratio of TrkB-TKþ:truncated TrkB protein was also decreased in people with schizophrenia and confirmed that this reduction extended to the protein level (unpaired t test: t = �2.01, df = 134, P = .02, one-tailed) (figure 4C).
The Effect of Gender on TrkB Expression
No significant main effect of gender or diagnosis 3 gender interaction was found for TrkB-TKþ mRNA expression by 2-way ANOVA (all F < 0.34, df = 1, 
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130, all P > .57). Strikingly, when we examined the expression levels of TrkB-TKþ protein, we found highly significant main effects of gender (F = 8.16, df = 1, 132, P = .005) and diagnosis 3 gender interaction (F = 7.23, df = 1, 132, P = .008) (figure 5). We found that control females expressed higher levels of TrkB-TKþ protein than control males (post hoc LSD, P = .0003) and that females with schizophrenia showed a significant reduction in TrkB-TKþ protein compared with control females (post hoc LSD, P = .0009).
No significant main effect of gender (F = 0.77, df = 1, 129, P = .38) or diagnosis 3 gender interaction effect (F = 0.001, df = 1, 129, P = .98) was observed for TrkB-TK� mRNA expression. For TrkB-Shc mRNA, no significant main effect of gender or diagnosis 3 gender interaction effect (both F < .91, df = 1, 132, P > 0.34) was observed. We did not detect a significant main effect of gender (F = 1.87, df = 1, 133, P = .16) or a significant diagnosis 3 gender interaction effect on truncated TrkB protein (F = 0.44, df = 1, 133, P = .51). No main effect of gender or diagnosis 3 gender interaction were observed for any of the ratio measures (all gender: F < 0.55, all P > .37).
Antipsychotics May Down-Regulate TrkB-TKþ mRNA
We next examined the relationship between clinical variables and TrkB mRNA expression in people with schizophrenia. TrkB-TKþ mRNA expression showed no significant correlation with age of onset or duration of illness (trend level) but was negatively correlated with lifetime antipsychotic use (r = �.50, P = .00003) (see online supplementary material for table S1). Considering that lifetime antipsychotic use is influenced by age, we conducted partial correlations and found a similar significant correlation between TrkB-TKþ mRNA and lifetime antipsychotic use (r = �.37, P = 0.003). TrkB-TK� and TrkB-Shc mRNA levels did not correlate with age of onset, duration of illness, or lifetime antipsychotic use (see online supplementary material for table S1). Data are expressed as quantity mean/geomean or TrkB density/b-actin density of individual subjects. **P < .01, *P < .05. Fig. 5 . Gender-specific changes in TrkB isoform expression in schizophrenia. Full-length TrkB (TrkB-TKþ) protein expression was grouped based on gender: females (white) and males (black). Protein expression of TrkB-TKþ was normalized by the corresponding internal controls; hence, expression levels are on the same scale. Data is expressed as TrkB-TKþ density/b-actin density of individual subjects. ***P < .001 compared with control females.
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130, all P > .57). Strikingly, when we examined the expression levels of TrkB-TKþ protein, we found highly significant main effects of gender (F = 8.16, df = 1, 132, P = .005) and diagnosis 3 gender interaction (F = 7.23, df = 1, 132, P = .008) (figure 5). We found that control females expressed higher levels of TrkB-TKþ protein than control males (post hoc LSD, P = .0003) and that females with schizophrenia showed a significant reduction in TrkB-TKþ protein compared with control females (post hoc LSD, P = .0009). No significant main effect of gender (F = 0.77, df = 1, 129, P = .38) or diagnosis 3 gender interaction effect (F = 0.001, df = 1, 129, P = .98) was observed for TrkB-TK� mRNA expression. For TrkB-Shc mRNA, no significant main effect of gender or diagnosis 3 gender interaction effect (both F < .91, df = 1, 132, P > 0.34) was observed. We did not detect a significant main effect of gender (F = 1.87, df = 1, 133, P = .16) or a significant diagnosis 3 gender interaction effect on truncated TrkB protein (F = 0.44, df = 1, 133, P = .51). No main effect of gender or diagnosis 3 gender interaction were observed for any of the ratio measures (all gender: F < 0.55, all P > .37).
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Antipsychotics May Down-Regulate TrkB-TKþ mRNA
We then determined whether the class of antipsychotics used by people with schizophrenia had differential effects on TrkB transcript expression. Considering that most cases were on both typical and atypical antipsychotics during their lifetime, we analyzed only those who were just on typical or atypical antipsychotics. In the schizophrenia group, we found that individuals on typical antipsychotics had significantly lower TrkB-TKþ mRNA levels (24% lower; ANOVA main effect: F = 14.09, df = 1, 47, P = .0005) compared with those individuals on atypical antipsychotics. TrkB-TK� and TrkB-Shc mRNA levels were comparable between groups (all P > .10).
When we examined the effect of clinical variables on TrkB protein, we found no significant correlations with expression of the TrkB-TKþ protein (see online supplementary material for table S1). Interestingly, we observed a significant positive correlation between truncated TrkB protein expression and lifetime antipsychotic use (r = .24, P = .05). However, when we controlled for the effect of age by partial correlation, the significance of antipsychotics on truncated TrkB protein expression was lost (r = .15, P = .23). Expression of truncated TrkB protein did not correlate with age of onset or duration of illness (see online supplementary material for table S1).
We found no significant difference in TrkB protein (both full-length and truncated) in people with schizophrenia on typical or atypical antipsychotics (all P > .40).
Relationship Between TrkB mRNA and GAD67 mRNA
Previously, a reduction in TrkB-TKþ mRNA expression was found to correlate with a reduction in GAD67 mRNA expression. 3 However, a relationship between either of the truncated TrkB receptors with GAD67 mRNA has yet to be demonstrated. Using the TRC cohort, we found a highly significant positive correlation between TrkB-TKþ and GAD67 mRNA levels (r = .69, P < .000001) (figure 6A). Conversely, a moderately strong negative correlation between TrkB-TK� and GAD67 mRNA was observed (r = �.32, P = .008) ( figure  6B ). TrkB-Shc and GAD67 mRNA expression were not significantly correlated (r = .19, P = .13) (figure 6C).
Relationship Between BDNF and TrkB Expression
In our previous study, we found a significant decrease in BDNF transcript II-IX and trends toward reduction in BDNF transcript VI-IX in the DLPFC of people with schizophrenia. 4 Considering that we find changes in TrkB transcripts in this current study, we determined whether changes in TrkB were correlated with BDNF. We found significant positive correlations between TrkB-TKþ mRNA levels and BDNF transcripts II-IX (r = .56, P = .000003) and IV-IX (r = .42, P = .0003); and significant negative correlations between TrkB-TK� mRNA and BDNF transcripts IV-IX (r = �.45, P = .0001) and VI-IX (r = �.33, P = .01). Moreover, a significant negative correlation was also found between expression of the truncated TrkB proteins and BDNF transcript II-IX (r = �.31, P = .02).
Discussion
The major finding we report is the novel and highly significant increase in both TrkB-TK� and TrkB-Shc Fig. 6 . Correlations between TrkB and GAD67 mRNA. GAD67 mRNA expression levels were positively correlated with (A) fulllength TrkB (TrkB-TKþ) (P < .000001) and (B) negatively correlated with truncated TrkB (TrkB-TK�) (P 5 .008) but not correlated with (C) sarc homology containing TrkB (TrkB-Shc) (P 5 .13). Diamonds represent control and squares represent schizophrenic cases.
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Discussion
The major finding we report is the novel and highly significant increase in both TrkB-TK� and TrkB-Shc mRNA levels in the DLPFC of people with schizophrenia. The increased expression of truncated TrkBs in schizophrenia was the most robust change found in this study using a large cohort (n = 144). Our finding of large increases in truncated TrkB mRNA levels, along with more limited increases in truncated TrkB proteins, suggests that additional to elevated steady-state levels of truncated TrkB protein, there is a possibility of greater TrkB-TK� and/or TrkB-Shc protein turnover and thus, a higher demand on mRNA synthesis. However, further studies examining the regulation of truncated TrkB mRNA are needed to determine if alterations in these mRNAs are primary in nature or are changed in response to alterations in TrkB signaling or usage in schizophrenia. Regardless of the molecular mechanism involved, our findings suggest that adequate stimulation of neurotrophin signaling in the cortex of people with schizophrenia will require not only augmentation of BDNF and TrkB-TKþ signaling but also simultaneous blocking of the increased truncated TrkBs.
Another novel finding we report is the reduction in the TrkB-TKþ:truncated TrkB ratios on the mRNA and protein levels. The fact that reductions in the TrkB-TKþ:truncated TrkB (both mRNA and protein) ratios were significant in both males and females with schizophrenia suggests that a reduced ratio of full-length to truncated TrkB may be a generalizable measure of altered neurotrophin response in schizophrenia. Indeed, increased TrkB-TK� and TrkB-Shc in neurons may act as dominant-negative receptors by forming inactive heterodimers with TrkB-TKþ (tyrosine kinase signaling requires 2 functional tyrosine kinase units) or compete with neuronal TrkB-TKþ homodimers for BDNF binding.
Finally, while we replicate previous observations of reduced TrkB-TKþ mRNA levels in the DLPFC of people with schizophrenia, 3, 11 the overall reduction we found was small and not statistically significant. However, we did find significant reductions in TrkB-TKþ mRNA in those people with schizophrenia on typical antipsychotics and the difference between our study and others may be because earlier cohorts had a greater proportion of patients on typical antipsychotics as compared with our study. Despite a modest reduction in TrkB-TKþ mRNA, a significant decrease was observed in TrkB-TKþ protein expression, consistent with a previous report that found a reduction in TrkB-TKþ protein in the DLPFC of people with schizophrenia. 33 However, when we examined gender-specific levels of TrkB-TKþ protein, we found that only females showed a significant reduction in schizophrenia, whereas males showed no change (please refer to the online supplementary material for Discussion). The age range of our cohort spanned young adulthood to aged (18-78 y) and consistent with previous findings.
3,11 we found that TrkB-TKþ mRNA continued to decrease gradually throughout adult life in the DLPFC.
Implications of Increased Truncated TrkB Isoforms
The neuronal response to BDNF is proposed to depend principally upon the relative levels of TrkB-TKþ and TrkB-TK�. 21, 24 While little has been reported on TrkBShc, this truncated isoform is unable to be phosphorylated by TrkB-TKþ, 13 suggesting that it shares a similar biological function to TrkB-TK�. However, dissimilar to TrkB-TK�, which can be expressed in multiple tissues and by both neurons (pyramidal and interneurons) and glia (astrocytes), [16] [17] [18] TrkB-Shc is brain-specific and neuronspecific. 13, 25 . This would suggest that in neuronal membranes, direct physical interactions between TrkB-TKþ and TrkB-Shc are likely to occur and that increased TrkB-Shc may be anatomically positioned to compromise neuronal second messenger activation by BDNF. Previously, we and others have found that cortical BDNF mRNA and protein are reduced in schizophrenia.
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When we correlated TrkB transcript levels with BDNF alternative transcript expression, 4 we found that expression of BDNF transcripts II-, IV-, and VI-IX were significantly correlated with TrkB-TKþ and TrkB-TK� mRNA levels. Importantly, BDNF transcript II-IX expression, the transcript we found most affected in the DLPFC in schizophrenia, 4 was significantly and negatively correlated with expression of the truncated TrkB protein. This finding suggests that changes in this ligand-receptor pair may be related or reflective of a shared underlying pathology and supports our hypothesis that alterations in BDNF, TrkB-TKþ, and/or truncated TrkB receptor expression may work in combination to alter neuronal neurotrophin signaling in the DLPFC of people with schizophrenia.
Interestingly, the diagnostic changes we observed in the ratios of TrkB-TKþ and the truncated TrkB receptors were very dramatic. Since neural activity upregulates BDNF and TrkB mRNA and that BDNF mRNA is decreased in schizophrenia, we expected to find a large decrease in overall TrkB levels. However, we only found subtle reductions in TrkB-TKþ mRNA despite the fact that some BDNF transcripts did positively correlate with TrkB-TKþ as would be expected if they were co-regulated. Instead, we found an increase in mRNA encoding truncated forms of TrkB and a negative correlation with BDNF mRNA. We speculate that the subtle decrease in TrkB-TKþ mRNA and dramatic increases in truncated TrkB receptors (TrkB-TK�/TrkBShc) may be due to alterations in TrkB splicing and increased stability of the truncated TrkB transcripts. Increases in the stability of truncated TrkB mRNAs coupled with increased translation may result in the different direction and magnitude of change observed between TrkB-TKþ and the truncated TrkB receptors. This is plausible as other transcripts associated with the schizophrenia neuropathology, such as BDNF, have demonstrated altered alternative transcript expression and posttranscriptional regulation in schizophrenia. 4, 34 Putative Cause/Consequence of Altered Cortical TrkB Alterations in TrkB ratios are associated with cortical maldevelopment. Deficits in neurotrophin signaling have been proposed as an upstream event in the neuropathology of schizophrenia. In particular, deficits in neurotrophin signaling may be a principle factor leading to deficiencies in cortical inhibitory interneurons in schizophrenia. 3, [35] [36] [37] Considering that BDNF is primarily synthesized by excitatory neurons, expression of TrkB-TKþ, particularly when expressed by the inhibitory interneurons, may be critical for enabling them to gain sufficient target-derived neurotrophic support. Indeed, reductions in cortical TrkB-TKþ and BDNF expression have been found to correlate with reductions in GAD67 mRNA, a key pathological hallmark of schizophrenia. 3, 38, 39 Previously, we found a significant reduction in GAD67 mRNA levels in the DLPFC of people with schizophrenia in our cohort 40 and in this current study, we found a highly significant positive correlation between TrkB-TKþ and GAD67 mRNA levels. Interestingly, we also found a significant negative correlation between TrkB-TK�, but not TrkB-Shc, and GAD67 mRNA. This would suggest that increased expression of TrkB-TK� in neurons and glia may be deleterious for interneuron health and viability as increased expression of TrkB-TK� would serve to limit the amount of BDNF secreted by pyramidal neurons for interneuron TrkB-TKþ binding. Together, these findings support the notion that adequate balance of TrkB isoforms may be crucial for proper cortical interneuron development, differentiation, and/or maintenance.
Increases in TrkB-TK� expression in glia may negatively impact interneuron function in several ways. An increase in glia-specific expression of TrkB-TK� may compete with interneurons for BDNF binding and reduce overall neurotrophic support to interneurons that do not produce BDNF. Alternatively, TrkB-TK� has been shown to be important in mediating calcium release from astrocytes. 41 An increase in TrkB-TK� expression in astrocytes may dysregulate calcium signaling and negatively impact interneuron health and viability. Interestingly, expression of the calcium binding protein, parvalbumin within a specific set of interneurons is consistently decreased in the prefrontal cortex in schizophrenia. 37, 42, 43 Furthermore, astrocytic TrkB-TK� is coupled to the Rho signaling pathway and TrkB-TK� is critical in regulating astrocyte morphology in response to BDNF 44 and changes in astrocyte morphology can impact communication at synapses where astrocytic processes are involved in neurotransmitter removal.
Potential Limitations
We found that TrkB-TKþ mRNA expression was correlated negatively with lifetime antipsychotic usage. However, when we grouped individuals with schizophrenia into the class of antipsychotics prescribed, we found that those on typical antipsychotics had lower levels of TrkB-TKþ mRNA compared with those on atypical antipsychotics. These findings would suggest that the trending reduction in TrkB-TKþ mRNA found in this study or the reduction in TrkB-TKþ mRNA found previously 3, 11 may have occurred as a consequence of antipsychotic medication. However, we previously found no significant correlation between TrkB-TKþ mRNA and lifetime antipsychotic exposure, 11 and previous studies have also found no change in TrkB-TKþ mRNA levels in the prefrontal cortex of monkeys after long-term exposure to haloperidol 3 or in the frontal cortex of rodents following chronic exposure to antipsychotics. 45, 46 Thus, antipsychotic usage may be a potential confound in this study, and further work delineating the effects of specific classes of antipsychotics on TrkB mRNA and protein expression in schizophrenia is required.
Conclusions
Our findings show for the first time that increases in truncated TrkB receptor isoforms may contribute to deficits in BDNF/TrkB signaling and neuronal plasticity in schizophrenia. However, the compromised signaling potential of BDNF/TrkB, be it from reduced BDNF, reduced TrkB-TKþ, or increased truncated TrkB receptors, would be expected to converge on the same consequence of reduced neurotrophic support for cortical neurons leading to impairments in inhibitory transmission and cortical plasticity in people with schizophrenia. Further work aimed at understanding how dysregulation of TrkB occurs in schizophrenia would be needed; however, our results suggest that there may be multiple points of dysregulation in this gene and gene product in schizophrenia. In particular, our study highlights the need to engineer treatments that can stimulate TrkB-TKþ function while attenuating the effects of truncated TrkBs if we are to restore proper BDNF signaling in the brains of people with schizophrenia. There are no conflicts of interest.
